Concern remains over Indian pharma’s sterile manufacturing practices, says Prosfora Tech MD

Indian pharma cos putting up ANDAs and APIs in one plant to avoid paying GDUFA fee, says Rajan.

“Between 25% and 30% of our total exposures are hedged.”

"There is a fresh wave of consolidation expected next year that could trigger another wave of price erosion."

According to a notification on USFDA's website, fee for Drug Master File was reduced to USD 47,829 for 2017-18 from USD 51,140 in the last ...

In an exclusive chat with ET Now, Saumen Chakraborty, CFO, Dr Reddy's, said that some of the drugs that were to be launched in Q4 has now b...

"Over 90 per cent of our revenues are still coming from Latin America and in the next couple of years we see the same trend continuing."

"If Ranbaxy would have continued, it would have become the best brand in India," says Amit Rajan, Director, Celogen Life Science.

"I think the approvals are definitely on the uptick. Inspections are a reality of life."

In an interaction with ET Now, Ramesh Swaminathan, CFO, Lupin, talks about company's prospectus and expansion plans.

"I can't share any numbers at this point. But I can tell you that H1 was very nice, much better than last year. We expect this year to be a...

If the dragon is going to stumble, there is going to be rumbling; China has the potential to be the blackest of black swan, says Dharamshi.

"Will have not very severe pricing erosion that would lead the way for earnings growth"